XML 57 R32.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Segment reporting | 12 Months Ended
--- | ---
Dec. 31, 2016
Segment Reporting [Abstract] |
Segment reporting |
25. | Segment reporting
The Company operates two major divisions, DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division is comprised of the Company’s U.S. dialysis and related lab services business, various ancillary services and strategic initiatives, including its international operations, and the Company’s corporate administrative support. The Company’s U.S. dialysis and related lab services business is its largest line of business, and is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as ESRD. The Company’s DMG division is a patient- and physician-focused integrated healthcare delivery and management company with over two decades of providing coordinated outcomes-based medical care in a cost-effective manner. The Company’s ancillary services and strategic initiatives consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care and the Company’s international operations. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company’s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer. The Company’s separate operating segments include its U.S. dialysis and related lab services business, its DMG operations in each region, each of its ancillary services and strategic initiatives, and its consolidated international kidney care and other health operations in the European and Middle Eastern, Latin American, and Asian Pacific markets, and under the Saudi Ministry of Health charter. The U.S. dialysis and related lab services business and the DMG business each qualify as separately reportable segments, and all other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category. The Company’s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial performance of the operating segments. For internal management reporting, segment operations include direct segment operating expenses but exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive-based compensation of certain departments which provide support to all of the Company’s various operating lines of business. These corporate administrative support costs are reduced by internal management fees received from the Company’s ancillary lines of business and were increased by the reduction of a tax asset associated with the DMG acquisition escrow provisions. The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
|  | Year ended December 31, |
|  | 2016 |  |  | 2015 |  |  | 2014 |
Segment revenues: |  |  |  |  |  |  |  |  |  |  |  |
U.S. dialysis and related lab services |  |  |  |  |  |  |  |  |  |  |  |
Patient service revenues: |  |  |  |  |  |  |  |  |  |  |  |
External sources |  | $ | 9,482,648 |  |  | $ | 8,980,515 |  |  | $ | 8,513,089 |
Intersegment revenues |  |  | 68,774 |  |  |  | 53,476 |  |  |  | 37,112 |
Total dialysis and related lab services revenues |  |  | 9,551,422 |  |  |  | 9,033,991 |  |  |  | 8,550,201 |
Less: Provision for uncollectible accounts |  |  | (429,882 | ) |  |  | (406,530 | ) |  |  | (353,028 | )
Net dialysis and related lab services patient service revenues |  |  | 9,121,540 |  |  |  | 8,627,461 |  |  |  | 8,197,173 |
Other revenues(1) |  |  | 16,649 |  |  |  | 13,971 |  |  |  | 13,498 |
Total net dialysis and related lab services revenues |  |  | 9,138,189 |  |  |  | 8,641,432 |  |  |  | 8,210,671 |
DMG |  |  |  |  |  |  |  |  |  |  |  |
DMG revenues: |  |  |  |  |  |  |  |  |  |  |  |
Capitated revenues |  | $ | 3,430,576 |  |  | $ | 3,436,705 |  |  | $ | 3,190,903 |
Net patient service revenues |  |  | 621,583 |  |  |  | 317,950 |  |  |  | 219,306 |
Other revenues(2) |  |  | 61,040 |  |  |  | 82,470 |  |  |  | 91,374 |
Intersegment capitated and other revenues |  |  | 215 |  |  |  | 136 |  |  |  | 716 |
Total revenues |  | $ | 4,113,414 |  |  | $ | 3,837,261 |  |  | $ | 3,502,299 |
Other - Ancillary services and strategic initiatives |  |  |  |  |  |  |  |  |  |  |  |
Net patient service revenues |  | $ | 228,459 |  |  | $ | 160,484 |  |  | $ | 122,087 |
Capitated revenues |  |  | 88,103 |  |  |  | 72,390 |  |  |  | 70,385 |
Other external sources |  |  | 1,245,929 |  |  |  | 1,123,882 |  |  |  | 927,492 |
Intersegment revenues |  |  | 58,881 |  |  |  | 25,674 |  |  |  | 19,535 |
Total ancillary services and strategic initiatives revenues |  |  | 1,621,372 |  |  |  | 1,382,430 |  |  |  | 1,139,499 |
Total net segment revenues |  |  | 14,872,975 |  |  |  | 13,861,123 |  |  |  | 12,852,469 |
Elimination of intersegment revenues |  |  | (127,870 | ) |  |  | (79,286 | ) |  |  | (57,363 | )
Consolidated net revenues |  | $ | 14,745,105 |  |  | $ | 13,781,837 |  |  | $ | 12,795,106 |
Segment operating margin (loss): |  |  |  |  |  |  |  |  |  |  |  |
U.S. dialysis and related lab services |  | $ | 1,777,014 |  |  | $ | 1,259,632 |  |  | $ | 1,637,626 |
DMG |  |  | (104,233 | ) |  |  | 33,929 |  |  |  | 214,983 |
Other—Ancillary services and strategic initiatives |  |  | 266,323 |  |  |  | (103,901 | ) |  |  | (24,456 | )
Total segment margin |  |  | 1,939,104 |  |  |  | 1,189,660 |  |  |  | 1,828,153 |
Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes: |  |  |  |  |  |  |  |  |  |  |  |
Corporate administrative support(3) |  |  | (44,561 | ) |  |  | (18,965 | ) |  |  | (13,012 | )
Consolidated operating income |  |  | 1,894,543 |  |  |  | 1,170,695 |  |  |  | 1,815,141 |
Debt expense |  |  | (414,382 | ) |  |  | (408,380 | ) |  |  | (410,294 | )
Debt refinancing and redemption charges |  |  | — |  |  |  | (48,072 | ) |  |  | (97,548 | )
Other income |  |  | 8,734 |  |  |  | 8,893 |  |  |  | 2,374 |
Consolidated income from continuing operations before income taxes |  | $ | 1,488,895 |  |  | $ | 723,136 |  |  | $ | 1,309,673 |
| (1) | Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a noncontrolling interest or which are wholly-owned by third parties.
| (2) | Includes medical consulting service fees and management fees for providing management and administrative services to unconsolidated joint ventures, as well as revenue related to the maintenance of existing physician networks.
| (3) | Corporate administrative support costs in 2016 also include $30,934 of an adjustment to reduce a tax asset associated with the DMG acquisition escrow provisions.
Depreciation and amortization expense by segment is as follows:
|  | December 31, |
|  | 2016 |  |  | 2015 |  |  | 2014 |
U.S. dialysis and related lab services |  | $ | 482,768 |  |  | $ | 438,238 |  |  | $ | 402,767 |
DMG |  |  | 210,755 |  |  |  | 174,118 |  |  |  | 169,485 |
Other - Ancillary services and strategic initiatives |  |  | 26,729 |  |  |  | 25,668 |  |  |  | 18,683 |
|  | $ | 720,252 |  |  | $ | 638,024 |  |  | $ | 590,935 |
Summary of assets by segment is as follows:
|  | December 31, |
|  | 2016 |  |  | 2015 |
Segment assets |  |  |  |  |  |  |  |
U.S. dialysis and related lab services (including equity investments of $66,924 and $29,801, respectively) |  | $ | 11,438,100 |  |  | $ | 11,591,507 |
DMG (including equity investments of $10,350 and $22,714, respectively) |  |  | 6,213,091 |  |  |  | 6,150,666 |
Other - Ancillary services and strategic initiatives(1) (including equity investments of $425,115 and $20,853, respectively) |  |  | 1,090,066 |  |  |  | 772,702 |
Consolidated assets |  | $ | 18,741,257 |  |  | $ | 18,514,875 |
| (1) | Includes approximately $96,396 and $ 69,519 in 2016 and 2015, respectively, of net property and equipment related to the Company’s international operations.
Expenditures for property and equipment by segment is as follows:
|  | December 31, |
|  | 2016 |  |  | 2015 |  |  | 2014 |
U.S. dialysis and related lab services |  | $ | 675,994 |  |  | $ | 584,513 |  |  | $ | 560,610 |
DMG |  |  | 84,399 |  |  |  | 66,800 |  |  |  | 27,885 |
Other - Ancillary services and strategic initiatives |  |  | 68,702 |  |  |  | 56,685 |  |  |  | 52,835 |
|  | $ | 829,095 |  |  | $ | 707,998 |  |  | $ | 641,330 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration